Ana Lleo

List of Publications by Year in Descending Order

134 papers	6,499 citations	44 h-index	78 g-index
167 ext. papers	8,137 ext. citations	7.1 avg, IF	5.6 L-index

#	Paper	IF	Citations
134	High prevalence of porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels.. *Liver International*, **2022**,	7.9	
133	Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges.. *World Journal of Gastroenterology*, **2022**, 28, 1430-1443	5.6	
132	Versatile Mass Spectrometry-Based Intraoperative Diagnosis of Liver Tumor in a Multiethnic Cohort. *Applied Sciences (Switzerland)*, **2022**, 12, 4244	2.6	1
131	Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases. *Vaccines*, **2022**, 10, 801	5.3	2
130	Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.. *Journal of Hepatology*, **2021**,	13.4	10
129	Small and Large Bile Ducts Intrahepatic Cholangiocarcinoma Classification: A Preliminary Feature-Based Study. *Lecture Notes in Computer Science*, **2021**, 237-244	0.9	
128	Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization. *Applied Sciences (Switzerland)*, **2021**, 11, 9342	2.6	0
127	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. *JHEP Reports*, **2021**, 3, 100248	10.3	10
126	Experimental liver models: From cell culture techniques to microfluidic organs-on-chip. *Liver International*, **2021**, 41, 1744-1761	7.9	4
125	Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study. *Expert Opinion on Drug Safety*, **2021**, 20, 839-843	4.1	1
124	High prevalence of multidrug-resistant bacteria in patients with pyogenic liver abscess following liver cancer loco-regional treatments. *Liver International*, **2021**, 41, 1909-1912	7.9	0
123	Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?. *Hepatology*, **2021**, 74, 2307	11.2	1
122	What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective. *United European Gastroenterology Journal*, **2021**, 9, 787	5.3	1
121	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. *Gastroenterology*, **2021**, 160, 2483-2495.e26	13.3	9
120	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. *Journal of Viral Hepatitis*, **2021**, 28, 558-568	3.4	0
119	Pembrolizumab-Induced Vanishing Bile Duct Syndrome: a Case Report. *SN Comprehensive Clinical Medicine*, **2021**, 3, 906-908	2.7	2
118	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. *Journal of Hepatology*, **2021**, 75, 572-581	13.4	8

117	Antimitochondrial Antibodies: from Bench to Bedside. *Clinical Reviews in Allergy and Immunology*, **2021**, 1	12.3	3
116	Primary biliary cholangitis. *Lancet, The*, **2020**, 396, 1915-1926	40	33
115	High mortality in COVID-19 patients with mild respiratory disease. *European Journal of Clinical Investigation*, **2020**, 50, e13314	4.6	21
114	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *New England Journal of Medicine*, **2020**, 383, 1522-1534	59.2	913
113	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. *American Journal of Gastroenterology*, **2020**, 115, 1066-1074	0.7	31
112	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. *Journal of Autoimmunity*, **2020**, 114, 102511	15.5	53
111	Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study. *Journal of Leukocyte Biology*, **2020**, 108, 715-721	6.5	6
110	Postsustained Virological Response Management in Hepatitis C Patients. *Seminars in Liver Disease*, **2020**, 40, 233-239	7.3	4
109	Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma. *Updates in Surgery*, **2020**, 72, 413-421	2.9	3
108	Identifying medical professionals at risk for in-hospital COVID-19 infection: a snapshot during a "tsunami" highlighting unexpected risks. *Global Health & Medicine*, **2020**, 2, 235-239	2.4	1
107	Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. *World Journal of Gastroenterology*, **2020**, 26, 4900-4918	5.6	10
106	Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. *European Journal of Gastroenterology and Hepatology*, **2020**, 33,	2.2	1
105	Is the outcome after hepatectomy for transitional hepatocholangiocarcinoma different from that of hepatocellular carcinoma and mass-forming cholangiocarcinoma? A case-matched analysis. *Updates in Surgery*, **2020**, 72, 671-679	2.9	4
104	COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2366-2368.e3	6.9	35
103	Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis. *Journal of Experimental Medicine*, **2020**, 217,	16.6	35
102	Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review. *Liver Cancer*, **2020**, 9, 15-27	9.1	33
101	Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?. *Hepatology*, **2020**, 72, 359-360	11.2	1
100	Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence. *Liver International*, **2020**, 40, 3117-3124	7.9	17

99	Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. *Cancers*, **2020**, 12,	6.6	14
98	Transcriptional Differences for COVID-19 Disease Map Genes between Males and Females Indicate a Different Basal Immunophenotype Relevant to the Disease. *Genes*, **2020**, 11,	4.2	5
97	Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. *Cancers*, **2020**, 12,	6.6	25
96	The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review. *Seminars in Liver Disease*, **2020**, 40, 34-48	7.3	23
95	Management of patients with autoimmune liver disease during COVID-19 pandemic. *Journal of Hepatology*, **2020**, 73, 453-455	13.4	40
94	Mesenchymal Stem Cells to Treat Digestive System Disorders: Progress Made and Future Directions. *Current Transplantation Reports*, **2019**, 6, 134-145	1.5	
93	Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery. *Journal of Gastrointestinal Surgery*, **2019**, 23, 2216-2224	3.3	13
92	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2076-2084.e2	6.9	27
91	The tumour microenvironment and immune milieu of cholangiocarcinoma. *Liver International*, **2019**, 39 Suppl 1, 63-78	7.9	47
90	The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. *Journal of Autoimmunity*, **2019**, 100, 17-26	15.5	18
89	Lights and Shadows on Fibrates as Second-Line Therapy of Primary Biliary Cholangitis. *Gastroenterology*, **2019**, 156, 1930-1931	13.3	
88	Safety of vedolizumab in liver transplant recipients: A systematic review. *United European Gastroenterology Journal*, **2019**, 7, 875-880	5.3	2
87	The risk of liver cancer in autoimmune liver diseases. *Therapeutic Advances in Medical Oncology*, **2019**, 11, 1758835919861914	5.4	13
86	Hepatotoxicity of immune check point inhibitors: Approach and management. *Digestive and Liver Disease*, **2019**, 51, 1074-1078	3.3	19
85	Role of liver biopsy in hepatocellular carcinoma. *World Journal of Gastroenterology*, **2019**, 25, 6041-6052	5.6	33
84	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. *Nutrients*, **2019**, 11,	6.7	27
83	Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 5-6	18.8	
82	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. *Digestive and Liver Disease*, **2019**, 51, 310-317	3.3	29

81	High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 1705-1712	6.1	21
80	The Epigenetics of Primary Biliary Cholangitis **2018**, 251-272		
79	The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. *Frontiers in Oncology*, **2018**, 8, 181	5.3	11
78	Common Variable Immunodeficiency and Liver Involvement. *Clinical Reviews in Allergy and Immunology*, **2018**, 55, 340-351	12.3	32
77	Is Liver Injury an Affordable Risk of Immune Checkpoint Inhibitor Therapy for Cancer?. *Gastroenterology*, **2018**, 155, 2021-2023	13.3	3
76	Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era. *Hepatobiliary and Pancreatic Diseases International*, **2018**, 17, 570-574	2.1	1
75	The impact of antiviral therapy on hepatocellular carcinoma epidemiology. *Hepatic Oncology*, **2018**, 5, HEP03	4	11
74	No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals. *Liver International*, **2018**, 38, 2342-2342.	7.9	
73	Changes in the Epidemiology of Primary Biliary Cholangitis. *Clinics in Liver Disease*, **2018**, 22, 429-441	4.6	11
72	SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study. *Journal of Hepatology*, **2018**, 68, S86	13.4	2
71	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. *Liver International*, **2017**, 37, 514-528	7.9	71
70	Human β-Defensin 2 in Primary Sclerosing Cholangitis. *Clinical and Translational Gastroenterology*, **2017**, 8, e80	4.2	3
69	Geoepidemiology and the Impact of Sex on Autoimmune Diseases **2017**, 323-333		
68	Primary biliary cholangitis: a comprehensive overview. *Hepatology International*, **2017**, 11, 485-499	8.8	65
67	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. *Gut*, **2016**, 65, 321-9	19.2	107
66	Making Sense of Autoantibodies in Cholestatic Liver Diseases. *Clinics in Liver Disease*, **2016**, 20, 33-46	4.6	17
65	Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. *PLoS ONE*, **2016**, 11, e0159612	3.7	19
64	The epigenetics of PBC: The link between genetic susceptibility and environment. *Clinics and Research in Hepatology and Gastroenterology*, **2016**, 40, 650-659	2.4	22

63	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. *Clinical and Experimental Immunology*, **2016**, 185, 61-71	6.2	59
62	Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. *Scientific Reports*, **2016**, 6, 25906	4.9	82
61	Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. *Immunobiology*, **2015**, 220, 1025-9	3.4	15
60	The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. *Digestive and Liver Disease*, **2015**, 47, 432-5	3.3	21
59	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. *Nature Communications*, **2015**, 6, 8019	17.4	185
58	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. *Gastroenterology*, **2015**, 149, 1804-1812.e4	13.3	235
57	DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. *Clinical Epigenetics*, **2015**, 7, 61	7.7	66
56	Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. *Mediators of Inflammation*, **2015**, 2015, 436450	4.3	20
55	Geoepidemiology, Genetic and Environmental Risk Factors for PBC. *Digestive Diseases*, **2015**, 33 Suppl 2, 94-101	3.2	24
54	Advances in pharmacotherapy for primary biliary cirrhosis. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 633-43	4	25
53	Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. *Digestive and Liver Disease*, **2014**, 46, 363-8	3.3	11
52	Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. *European Journal of Immunology*, **2014**, 44, 945-54	6.1	26
51	What Is an Autoantibody? **2014**, 13-20		1
50	Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. *Hepatology*, **2014**, 60, 1314-23	11.2	64
49	Genetics and epigenetics of primary biliary cirrhosis. *Seminars in Liver Disease*, **2014**, 34, 255-64	7.3	35
48	Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. *Gastroenterology*, **2014**, 147, 1338-49.e5; quiz e15	13.3	265
47	Role of cholangiocytes in primary biliary cirrhosis. *Seminars in Liver Disease*, **2014**, 34, 273-84	7.3	25
46	Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis. *Frontiers in Immunology*, **2014**, 5, 128	8.4	46

45	Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. *Hepatology*, **2013**, 57, 1498-508	11.2	46
44	Apotopes and innate immune system: novel players in the primary biliary cirrhosis scenario. *Digestive and Liver Disease*, **2013**, 45, 630-6	3.3	17
43	The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. *Journal of Autoimmunity*, **2013**, 46, 81-7	15.5	52
42	Y chromosome loss in male patients with primary biliary cirrhosis. *Journal of Autoimmunity*, **2013**, 41, 87-91	15.5	73
41	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. *Genes and Immunity*, **2013**, 14, 179-86	4.4	44
40	Geoepidemiology, gender and autoimmune disease. *Autoimmunity Reviews*, **2012**, 11, A386-92	13.6	100
39	Autoimmunity and Turner's syndrome. *Autoimmunity Reviews*, **2012**, 11, A538-43	13.6	55
38	X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. *Clinical and Experimental Immunology*, **2012**, 169, 253-62	6.2	47
37	Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. *Hepatology*, **2012**, 55, 153-60	11.2	93
36	The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. *Autoimmunity Highlights*, **2012**, 3, 127-32	3.7	2
35	Towards common denominators in primary biliary cirrhosis: the role of IL-12. *Journal of Hepatology*, **2012**, 56, 731-3	13.4	35
34	Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. *Journal of Autoimmunity*, **2012**, 38, J193-6	15.5	47
33	The X chromosome and immune associated genes. *Journal of Autoimmunity*, **2012**, 38, J187-92	15.5	199
32	Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. *BMC Gastroenterology*, **2012**, 12, 92	3	23
31	Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. *Hepatology*, **2012**, 55, 1495-506	11.2	24
30	Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. *Human Molecular Genetics*, **2012**, 21, 5209-21	5.6	122
29	Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. *Genes and Immunity*, **2012**, 13, 461-8	4.4	66
28	Modulation of CD4+ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. *Clinical and Experimental Immunology*, **2011**, 165, 243-50	6.2	31

27	Primary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes. *Journal of Gastroenterology*, **2011**, 46 Suppl 1, 29-38	6.9	25
26	Immunopathogenesis of primary biliary cirrhosis: an old wives tale. *Immunity and Ageing*, **2011**, 8, 12	9.7	22
25	B cell depletion therapy exacerbates murine primary biliary cirrhosis. *Hepatology*, **2011**, 53, 527-35	11.2	56
24	Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. *Hepatology*, **2011**, 54, 196-203	11.2	48
23	Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. *Epigenetics*, **2011**, 6, 95-102	5.7	64
22	Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. *American Journal of Physiology - Renal Physiology*, **2011**, 301, G623-33	5.1	41
21	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. *Nature Genetics*, **2010**, 42, 658-60	36.3	337
20	Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. *Journal of Hepatology*, **2010**, 52, 712-7	13.4	40
19	Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. *Journal of Autoimmunity*, **2010**, 35, 176-80	15.5	58
18	PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. *Journal of Autoimmunity*, **2010**, 35, 436-42	15.5	103
17	Definition of human autoimmunity--autoantibodies versus autoimmune disease. *Autoimmunity Reviews*, **2010**, 9, A259-66	13.6	171
16	Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. *Hepatology*, **2010**, 52, 987-98	11.2	154
15	Innate immunity and primary biliary cirrhosis. *Current Molecular Medicine*, **2009**, 9, 45-51	2.5	52
14	The immunological potential of galectin-1 and -3. *Autoimmunity Reviews*, **2009**, 8, 360-3	13.6	82
13	Apotopes and the biliary specificity of primary biliary cirrhosis. *Hepatology*, **2009**, 49, 871-9	11.2	158
12	Primary biliary cirrhosis is associated with altered hepatic microRNA expression. *Journal of Autoimmunity*, **2009**, 32, 246-53	15.5	167
11	Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. *Annals of the New York Academy of Sciences*, **2009**, 1173, 847-57	6.5	11
10	Is autoimmunity a matter of sex?. *Autoimmunity Reviews*, **2008**, 7, 626-30	13.6	143

9	The consequences of apoptosis in autoimmunity. *Journal of Autoimmunity*, **2008**, 31, 257-62	15.5	98
8	Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. *Hepatology*, **2008**, 48, 1906-12	11.2	98
7	Etiopathogenesis of primary biliary cirrhosis. *World Journal of Gastroenterology*, **2008**, 14, 3328-37	5.6	72
6	Interpreting serological tests in diagnosing autoimmune liver diseases. *Seminars in Liver Disease*, **2007**, 27, 161-72	7.3	87
5	Autophagy: highlighting a novel player in the autoimmunity scenario. *Journal of Autoimmunity*, **2007**, 29, 61-8	15.5	83
4	Primary Biliary Cirrhosis and Autoimmune Cholangitis **2007**, 235-247		1
3	HLA class II antigens associated with lupus nephritis in Italian SLE patients. *Human Immunology*, **2003**, 64, 462-8	2.3	44
2	Transcriptional differences for COVID-19 Disease Map genes between males and females indicate a different basal immunophenotype relevant to the disease		1
1	New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations		2